InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,303.27
(
0.12%
)
US TECH 100
18,062.00
(
-0.10%
)
Dow Jones
40,003.59
(
0.34%
)
Brent Oil
83.76
(
0.00%
)
Bitcoin
66,976.92
(
-0.15%
)
Post# of 251852
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119659
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 209104

Tuesday, 02/13/2018 7:21:34 PM

Tuesday, February 13, 2018 7:21:34 PM

Post# of 251852
MRK—BACE-inhibitor prodromal phase-3 stopped for futility:

https://www.businesswire.com/news/home/20180213006582/en

This trial had been scheduled to read out in 2019 (#msg-128708268).

The drug in question, Verubecestat, has now failed phase-3 AD trials in both the both mild-to-moderate and prodromol populations.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up